Clinical trial · Interventional
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rimiducid may be administered as indicated | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- P-BCMA-101 treated
- description
- Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
- interventionNames
- Drug: Rimiducid may be administered as indicated
Primary outcomes (1)
- measure
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- timeFrame
- Treatment with P-BCMA-101 through year 15
- description
- Incidence and severity of treatment-emergent adverse events to evaluate the long-term safety of P-BCMA-101
Secondary outcomes (11)
- measure
- Anti-myeloma effect of P-BCMA-101 (Response Rate)
- timeFrame
- Treatment with P-BCMA-101 through year 15
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol. * Subject has provided informed consent. Exclusion Criteria: * None
References
Publications (0)
Data not yet available